ArticleJournal of managed care & specialty pharmacy2022

Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.

Michelle Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.